Abstract
Background: We performed the first test in humans of whether aspirin at clinically relevant doses increases nitric oxide (NO) formation. Methods: Seventy primary prevention patients with metabolic syndrome were randomly assigned to 81 mg, 162.5 mg, 325 mg, 650 mg, or 1300 mg aspirin daily for 12 weeks to test changes in heme oxygenase (HO-1), a downstream target of NO formation and asymmetrical dimethylarginine (ADMA), a competitive inhibitor of NO synthase. Findings: For HO-1, the mean was 29.37 nanograms per milliliter at baseline and 57.45 at 12 weeks giving a mean ratio (MR) of 1.96 (P
Original language | English (US) |
---|---|
Pages (from-to) | 344-348 |
Number of pages | 5 |
Journal | Journal of Cardiovascular Pharmacology and Therapeutics |
Volume | 15 |
Issue number | 4 |
DOIs | |
State | Published - Dec 2010 |
Externally published | Yes |
Keywords
- atherosclerosis
- cardiovascular disease
- endothelium
- thrombosis
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Cardiology and Cardiovascular Medicine